Progress on omalizumab treatment for refractory asthma in children
10.3760/cma.j.issn.1673-4408.2023.09.010
- VernacularTitle:奥马珠单抗治疗儿童难治性哮喘的研究进展
- Author:
Yuze WEI
1
;
Zhiying HAN
Author Information
1. 山西医科大学儿科医学系，太原 030000
- Keywords:
Children;
Refractory asthma;
Immunoglobulin E;
Omalizumab
- From:
International Journal of Pediatrics
2023;50(9):619-623
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of refractory asthma in children is increasing year by year, bringing a heavy disease burden to families and society.As the immunological, pathophysiological and neurological mechanisms of asthma be elucidated, typeⅠallergic reactions mediated by the immunoglobulin E play an important role in the development of asthma.Omalizumab, targeting IgE, is using in clinical.This paper reviews the mechanism of action and clinical efficacy of omalizumab based on a review of the pathogenesis of refractory asthma, with the aim of guiding the individualized treatment of children with refractory asthma, improving the overall control rate.
